MRI-Guided Risk-Adaptive High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: A Phase II Trial
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S284
DOI: 10.1016/j.ijrobp.2026.06.598 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von B. Thomsen und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Thomsen, B., Harris, T., Buzurovic, I., Shin, K., Chirmade, S., Boyajian, R., Kowtoniuk, A., Smart, A., Orio, P., & King, M. (2026). MRI-Guided Risk-Adaptive High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: A Phase II Trial. International Journal of Radiation Oncology*Biology*Physics, 126(1), S284. https://doi.org/10.1016/j.ijrobp.2026.06.598
Vancouver
Thomsen B, Harris T, Buzurovic I, Shin K, Chirmade S, Boyajian R, et al. MRI-Guided Risk-Adaptive High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: A Phase II Trial. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S284. doi:10.1016/j.ijrobp.2026.06.598
BibTeX
@article{Thomsen2026,
author = {Thomsen, B. and Harris, T.C. and Buzurovic, I. and Shin, K.Y. and Chirmade, S. and Boyajian, R.N. and Kowtoniuk, A.M. and Smart, A.C. and Orio, P.F. and King, M.T.},
title = {MRI-Guided Risk-Adaptive High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: A Phase II Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {S284},
doi = {10.1016/j.ijrobp.2026.06.598}
}
EUVIMED